These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25061049)

  • 1. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.
    Wong CL; Bansback N; Lee PE; Anis AH
    Can J Neurol Sci; 2009 Nov; 36(6):735-9. PubMed ID: 19960752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the societal impact of acetylcholinesterase inhibitor therapies.
    Winblad B; Wimo A
    Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine: pharmacological properties and clinical uses.
    Kumar S
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
    Baskys A; Cheng JX
    Exp Gerontol; 2012 Nov; 47(11):887-91. PubMed ID: 22796225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic effect of cholinesterase inhibitor therapy: implications for managed care.
    Sano M
    Manag Care Interface; 2004 Aug; 17(8):44-9. PubMed ID: 15471110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
    Zala D; Chan D; McCrone P
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of Alzheimer's disease and the value of effective therapies.
    Stefanacci RG
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S356-62. PubMed ID: 22214393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    López-Bastida J; Hart W; García-Pérez L; Linertová R
    J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.